The Problem of HCC and Liver Transplantation
The treatment of hepatocellular carcinoma (HCC) is complex. During the last 10 years, efforts have been made to clarify the prognosis and treatment HCC, which is an increasing problem all over the world. The presence of a primary tumor within underlying cirrhotic disease, usually related to hepatitis C, makes the therapeutic approach of these patients complex.
Recently 2 scientific associations, the European Association of the Study of the Liver and the American Association of the Study of Liver Disease (EASL and AASLD), agreed to endorse a common HCC classification and treatment schedule, that of the Barcelona Clinic Liver Cancer Group, making it possible to evaluate prognosis by taking into account both the stage of the tumor and the stage of the cirrhosis.
It is clear that liver transplantation in the context of HCC that meets the Milan criteria has good results, with a probability of 5-year survival of well over 75% and a recurrence rate of ฯฝ15%. However, this only accounts for a small proportion of patients (20%); most patients with HCC have disease that is suitable for only locoregional or systemic treatment. The organ shortage